Radioimmunotherapy of Infectious Diseases

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The need for novel approaches to treat infectious diseases is obvious and urgent. This situation has renewed interest in the use of monoclonal antibodies (mAbs) to treat infectious diseases. During the last 5 years, radioimmunotherapy (RIT), a modality developed for cancer treatment, has been successfully adapted for the treatment of experimental fungal (C. neoformans and H. capsulatum), bacterial (S. pneumoniae and B. anthracis), and viral (HIV-1) infections. RIT produced none or only transient hematological toxicity in experimental animals. Investigation of radiobiological mechanisms of RIT of infections showed that microbial cells are killed by both "direct-hit" and "cross-fire" radiation. mAbs radiolabeled with either alpha- or beta-emitters stimulated apoptosis-like cell death, whereas only mAbs radiolabeled with alpha-emitter 213Bi also decreased the metabolic activity of microbial cells. The success of this approach in laboratory studies, combined with earlier nuclear medicine experience in preclinical and clinical studies using radiolabeled organism-specific antibodies for imaging of infections, provides encouragement for the feasibility of therapeutically targeting microbes with labeled antibodies. We envision that first the organism-specific mAbs will be radiolabeled with imaging radionuclides such as 99mTc or 111In to localize the sites of infection with single-photon emission computed tomography, followed by RIT with 188Re- or 90Y-labeled mAb, respectively. Also, immuno-position emission tomogrpahy might be used to image infection before treatment if such positron-emitting radionuclides as 86Y (matching pair for 90Y) or 124I (matching pair for 131I) are available. It might be possible to create a so-called "pan-antibody" that would recognize an antigen shared by a particular class of human pathogens such as fungi, for example. The availability of such antibodies would eliminate the necessity of having antibodies specific for each particular microorganism and would enormously enhance the development of RIT of infectious diseases.

Original languageEnglish (US)
Pages (from-to)146-153
Number of pages8
JournalSeminars in Nuclear Medicine
Volume39
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Radioimmunotherapy
Communicable Diseases
Monoclonal Antibodies
Antibodies
Infection
Bacterial Pneumonia
Nuclear Medicine
Single-Photon Emission-Computed Tomography
Radioisotopes
Radionuclide Imaging
HIV Infections
HIV-1
Fungi
Cell Death
Therapeutics
Electrons
Radiation
Apoptosis
Antigens
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radioimmunotherapy of Infectious Diseases. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Seminars in Nuclear Medicine, Vol. 39, No. 2, 03.2009, p. 146-153.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Casadevall, Arturo. / Radioimmunotherapy of Infectious Diseases. In: Seminars in Nuclear Medicine. 2009 ; Vol. 39, No. 2. pp. 146-153.
@article{4bc02e4a6c8c43ebbd774563b44679b6,
title = "Radioimmunotherapy of Infectious Diseases",
abstract = "The need for novel approaches to treat infectious diseases is obvious and urgent. This situation has renewed interest in the use of monoclonal antibodies (mAbs) to treat infectious diseases. During the last 5 years, radioimmunotherapy (RIT), a modality developed for cancer treatment, has been successfully adapted for the treatment of experimental fungal (C. neoformans and H. capsulatum), bacterial (S. pneumoniae and B. anthracis), and viral (HIV-1) infections. RIT produced none or only transient hematological toxicity in experimental animals. Investigation of radiobiological mechanisms of RIT of infections showed that microbial cells are killed by both {"}direct-hit{"} and {"}cross-fire{"} radiation. mAbs radiolabeled with either alpha- or beta-emitters stimulated apoptosis-like cell death, whereas only mAbs radiolabeled with alpha-emitter 213Bi also decreased the metabolic activity of microbial cells. The success of this approach in laboratory studies, combined with earlier nuclear medicine experience in preclinical and clinical studies using radiolabeled organism-specific antibodies for imaging of infections, provides encouragement for the feasibility of therapeutically targeting microbes with labeled antibodies. We envision that first the organism-specific mAbs will be radiolabeled with imaging radionuclides such as 99mTc or 111In to localize the sites of infection with single-photon emission computed tomography, followed by RIT with 188Re- or 90Y-labeled mAb, respectively. Also, immuno-position emission tomogrpahy might be used to image infection before treatment if such positron-emitting radionuclides as 86Y (matching pair for 90Y) or 124I (matching pair for 131I) are available. It might be possible to create a so-called {"}pan-antibody{"} that would recognize an antigen shared by a particular class of human pathogens such as fungi, for example. The availability of such antibodies would eliminate the necessity of having antibodies specific for each particular microorganism and would enormously enhance the development of RIT of infectious diseases.",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2009",
month = "3",
doi = "10.1053/j.semnuclmed.2008.10.007",
language = "English (US)",
volume = "39",
pages = "146--153",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Radioimmunotherapy of Infectious Diseases

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2009/3

Y1 - 2009/3

N2 - The need for novel approaches to treat infectious diseases is obvious and urgent. This situation has renewed interest in the use of monoclonal antibodies (mAbs) to treat infectious diseases. During the last 5 years, radioimmunotherapy (RIT), a modality developed for cancer treatment, has been successfully adapted for the treatment of experimental fungal (C. neoformans and H. capsulatum), bacterial (S. pneumoniae and B. anthracis), and viral (HIV-1) infections. RIT produced none or only transient hematological toxicity in experimental animals. Investigation of radiobiological mechanisms of RIT of infections showed that microbial cells are killed by both "direct-hit" and "cross-fire" radiation. mAbs radiolabeled with either alpha- or beta-emitters stimulated apoptosis-like cell death, whereas only mAbs radiolabeled with alpha-emitter 213Bi also decreased the metabolic activity of microbial cells. The success of this approach in laboratory studies, combined with earlier nuclear medicine experience in preclinical and clinical studies using radiolabeled organism-specific antibodies for imaging of infections, provides encouragement for the feasibility of therapeutically targeting microbes with labeled antibodies. We envision that first the organism-specific mAbs will be radiolabeled with imaging radionuclides such as 99mTc or 111In to localize the sites of infection with single-photon emission computed tomography, followed by RIT with 188Re- or 90Y-labeled mAb, respectively. Also, immuno-position emission tomogrpahy might be used to image infection before treatment if such positron-emitting radionuclides as 86Y (matching pair for 90Y) or 124I (matching pair for 131I) are available. It might be possible to create a so-called "pan-antibody" that would recognize an antigen shared by a particular class of human pathogens such as fungi, for example. The availability of such antibodies would eliminate the necessity of having antibodies specific for each particular microorganism and would enormously enhance the development of RIT of infectious diseases.

AB - The need for novel approaches to treat infectious diseases is obvious and urgent. This situation has renewed interest in the use of monoclonal antibodies (mAbs) to treat infectious diseases. During the last 5 years, radioimmunotherapy (RIT), a modality developed for cancer treatment, has been successfully adapted for the treatment of experimental fungal (C. neoformans and H. capsulatum), bacterial (S. pneumoniae and B. anthracis), and viral (HIV-1) infections. RIT produced none or only transient hematological toxicity in experimental animals. Investigation of radiobiological mechanisms of RIT of infections showed that microbial cells are killed by both "direct-hit" and "cross-fire" radiation. mAbs radiolabeled with either alpha- or beta-emitters stimulated apoptosis-like cell death, whereas only mAbs radiolabeled with alpha-emitter 213Bi also decreased the metabolic activity of microbial cells. The success of this approach in laboratory studies, combined with earlier nuclear medicine experience in preclinical and clinical studies using radiolabeled organism-specific antibodies for imaging of infections, provides encouragement for the feasibility of therapeutically targeting microbes with labeled antibodies. We envision that first the organism-specific mAbs will be radiolabeled with imaging radionuclides such as 99mTc or 111In to localize the sites of infection with single-photon emission computed tomography, followed by RIT with 188Re- or 90Y-labeled mAb, respectively. Also, immuno-position emission tomogrpahy might be used to image infection before treatment if such positron-emitting radionuclides as 86Y (matching pair for 90Y) or 124I (matching pair for 131I) are available. It might be possible to create a so-called "pan-antibody" that would recognize an antigen shared by a particular class of human pathogens such as fungi, for example. The availability of such antibodies would eliminate the necessity of having antibodies specific for each particular microorganism and would enormously enhance the development of RIT of infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=58849115567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849115567&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2008.10.007

DO - 10.1053/j.semnuclmed.2008.10.007

M3 - Article

VL - 39

SP - 146

EP - 153

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 2

ER -